Displaying 21–30 of 704 results
May 9, 2022
Editas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
May 6, 2022
The study is an important step toward a clinical trial of the approach
May 2, 2022
The company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
The live meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
The goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
The Basil and Karen Petrou Education Initiative is born of the Foundation’s commitment to helping individuals ensure their estates do the best they can for their loved ones and the causes they care about. Debuting this year, the program will offer ongoing resources to help individuals and families explore and learn about end-of-life plans and strategies.
Apr 26, 2022
Kenyetta has worked to help others through the nonprofit sector for over 25 years, despite being diagnosed with Stargardt disease at the age of 31. Kenyetta is now the chief operating officer of REACH Riverside Development Corporation and has been recognized for her career achievements by many.
Apr 25, 2022
The Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
Apr 22, 2022
The Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
Apr 13, 2022
Recent developments in research on age-related macular degeneration.